ERBB2 and breast cancer: The relative percentage of HER2+ (7/19 [36.8%]) but also of prognostically unfavorable triple-negative (ER-/PR-/HER2-) cases was similar to a recently reported large cohort of breast cancer patients with CNS metastases [35].